Zhejiang Medicine Overview
- Status
-
Public
- Employees
-
5,815
- Stock Symbol
-
600216
- Investments
-
3
- Share Price
-
$2.15
- (As of Friday Closing)
Zhejiang Medicine General Information
Description
Zhejiang Medicine Co Ltd is a china-based pharmaceutical company. The company manufactures fat-soluble vitamins, vitamins, quinolones, and antibiotic-resistant antibiotics, vitamin E, natural vitamin E, beta-carotene, cantharidin, vancomycin hydrochloride, and teicoplanin.
Contact Information
Website
www.zmc.topCorporate Office
- 168 Zhiyuan Middle Avenue
- Binhai New Town
- Shaoxing, Zhejiang 312366
- China
Corporate Office
- 168 Zhiyuan Middle Avenue
- Binhai New Town
- Shaoxing, Zhejiang 312366
- China
Zhejiang Medicine Stock Performance
As of 18-Jul-2025, Zhejiang Medicine’s stock price is $2.15. Its current market cap is $2.07B with 962M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.15 | $2.16 | $1.58 - $2.71 | $2.07B | 962M | 29.7M | $0.21 |
Zhejiang Medicine Financials Summary
As of 31-Mar-2025, Zhejiang Medicine has a trailing 12-month revenue of $1.3B.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 1,641,725 | 1,954,310 | 1,384,036 | 1,556,491 |
| Revenue | 1,302,045 | 1,306,567 | 1,101,665 | 1,205,102 |
| EBITDA | 217,148 | 270,248 | 155,491 | 177,136 |
| Net Income | 202,625 | 161,733 | 60,727 | 80,120 |
| Total Assets | 1,926,905 | 1,889,765 | 1,802,830 | 1,802,011 |
| Total Debt | 109,681 | 102,523 | 113,061 | 116,212 |
Zhejiang Medicine Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Zhejiang Medicine Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Zhejiang Medicine Patents
Zhejiang Medicine Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-12239613-B2 | Preparation method for carotenoid preparation having high bioavailability and high stability | Active | 18-Mar-2019 | ||
| US-20220160653-A1 | Preparation method for carotenoid preparation having high bioavailability and high stability | Active | 18-Mar-2019 | ||
| US-12302931-B2 | Solid beverage containing barley leaves and preparation method thereof | Active | 24-Jan-2019 | ||
| US-20220095650-A1 | Solid beverage containing barley leaves and preparation method thereof | Active | 24-Jan-2019 | ||
| US-11696937-B2 | Glycopeptide compounds having activity of resisting drug-resistant bacteria, and preparation method and application thereof | Active | 06-Mar-2018 | A61K38/14 |
Zhejiang Medicine Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Zhejiang Medicine Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Zhejiang Medicine Investments (3)
Zhejiang Medicine’s most recent deal was a Later Stage VC with Derlead Biotech. The deal was made on 05-Aug-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Derlead Biotech | 05-Aug-2022 | Later Stage VC | Diagnostic Equipment | ||
| Guobang Pharmaceutical | 30-Aug-2019 | PE Growth/Expansion | Pharmaceuticals | ||
| Zhejiang Sunmy Bio-Medical | 27-Sep-2011 | Joint Venture | Drug Discovery |
Zhejiang Medicine ESG
Risk Overview
Risk Rating
Updated February, 24, 2024
32.46 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,697
Rank
Percentile
Pharmaceuticals
Industry
of 847
Rank
Percentile
Pharmaceuticals
Subindustry
of 420
Rank
Percentile
Zhejiang Medicine Exits (2)
Zhejiang Medicine’s most recent exit was on 30-Aug-2019 from Guobang Pharmaceutical. The exit was categorized as with 7 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Guobang Pharmaceutical | 30-Aug-2019 | Completed |
|
||
| Zhejiang Sunmy Bio-Medical | 27-Sep-2011 | Joint Venture | Completed |
|
Zhejiang Medicine Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| NovoCodex Biopharmaceuticals | Shaoxing, China | 2017 |
Zhejiang Medicine FAQs
-
Where is Zhejiang Medicine headquartered?
Zhejiang Medicine is headquartered in Shaoxing, China.
-
What is the size of Zhejiang Medicine?
Zhejiang Medicine has 5,815 total employees.
-
What industry is Zhejiang Medicine in?
Zhejiang Medicine’s primary industry is Pharmaceuticals.
-
Is Zhejiang Medicine a private or public company?
Zhejiang Medicine is a Public company.
-
What is Zhejiang Medicine’s stock symbol?
The ticker symbol for Zhejiang Medicine is 600216.
-
What is the current stock price of Zhejiang Medicine?
As of 18-Jul-2025 the stock price of Zhejiang Medicine is $2.15.
-
What is the current market cap of Zhejiang Medicine?
The current market capitalization of Zhejiang Medicine is $2.07B.
-
What is Zhejiang Medicine’s current revenue?
The trailing twelve month revenue for Zhejiang Medicine is $1.3B.
-
What is Zhejiang Medicine’s annual earnings per share (EPS)?
Zhejiang Medicine’s EPS for 12 months was $0.21.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
